Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Viatris Inc. VTRS
$9.31
-$0.05 (-0.56%)
На 18:03, 12 мая 2023
+45.01%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
11726318269.00000000
-
week52high
12.40
-
week52low
8.42
-
Revenue
16262700000
-
P/E TTM
5
-
Beta
1.17577800
-
EPS
1.71000000
-
Last Dividend
0.48000000
-
Next Earnings Date
08 мая 2023 г. в 12:30
Описание компании
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| BMO Capital | Outperform | Outperform | 09 авг 2022 г. |
| UBS | Sell | 14 июн 2022 г. | |
| Goldman Sachs | Neutral | Neutral | 12 мая 2022 г. |
| Piper Sandler | Underweight | Neutral | 10 мая 2022 г. |
| Piper Sandler | Neutral | Neutral | 16 мар 2022 г. |
| Barclays | Overweight | Overweight | 25 окт 2022 г. |
| Jefferies | Hold | 21 окт 2022 г. | |
| UBS | Neutral | Sell | 10 ноя 2022 г. |
| Piper Sandler | Neutral | Underweight | 08 ноя 2022 г. |
| JP Morgan | Neutral | Neutral | 15 ноя 2022 г. |
| Barclays | Overweight | Overweight | 01 февр 2023 г. |
| Jefferies | Buy | Hold | 27 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Ni Xiangyang (Sean) | D | 29165 | 12800 | 25 ноя 2022 г. |
| Ni Xiangyang (Sean) | D | 0 | 1828 | 23 ноя 2022 г. |
| Ni Xiangyang (Sean) | D | 0 | 1828 | 23 ноя 2022 г. |
| Ni Xiangyang (Sean) | A | 41965 | 1829 | 23 ноя 2022 г. |
| Ni Xiangyang (Sean) | A | 40136 | 29815 | 23 ноя 2022 г. |
| van der Meer Mohr Pauline | D | 20543 | 9440 | 17 авг 2022 г. |
| Taddese Menassie | D | 0 | 8813 | 27 мая 2022 г. |
| Ni Xiangyang (Sean) | D | 0 | 102 | 29 мар 2022 г. |
| Ni Xiangyang (Sean) | D | 0 | 102 | 29 мар 2022 г. |
| Ni Xiangyang (Sean) | A | 10321 | 102 | 29 мар 2022 г. |
Новостная лента
2 Superb Dividend Stocks to Buy Today and Hold Forever
The Motley Fool
24 янв 2023 г. в 05:36
These two companies have long runways for growth and decent yields today.
Viatris: Where Is The Cure?
Seeking Alpha
23 янв 2023 г. в 02:46
Viatris has seen a disappointing performance since its 2019 mega tie-up. Sales and EBITDA have fallen a bit, as leverage has fallen a bit further.
Could This New Drug Launch Be a Hit for Viatris?
The Motley Fool
12 янв 2023 г. в 08:00
Viatris and Kindeva Drug Delivery could soon launch a generic version of AstraZeneca's Symbicort.
Viatris Inc. (VTRS) 41st Annual J.P. Morgan Healthcare Conference (Transcript)
Seeking Alpha
11 янв 2023 г. в 23:30
Viatris Inc. (NASDAQ:VTRS ) 41st Annual J.P. Morgan Healthcare Conference January 11, 2023 6:00 PM ET Company Participants Michael Goettler - CEO Rajiv Malik - President Jeffrey Nau - Head, Eye Care Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon.
Is Now the Time to Buy 3 of the S&P 500's Cheapest Stocks?
The Motley Fool
04 янв 2023 г. в 05:05
All of these stocks are trading at less than 7 times their future profits.